Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Andrew Burns

Physician Assistant, Medical Indianapolis, IN Physician Assistant

NPI 1487806006 CMS profile 11154973

10485 N Pennsylvania St, Suite 150, Indianapolis, IN 46280

Open in the dashboard

General payments

$12,857

940 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Burns of Indianapolis, IN is reported in the CMS Open Payments database as having received $12,857 across 940 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,410 204
2024 General $2,117 133
2023 General $2,610 196
2022 General $2,771 218
2021 General $2,950 189

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Burns
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Andrew Burns were reported at $2,410. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Andrew Burns Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,950 $156 $41–$563 $132
2022 $2,771 $185 $55–$649 $149
2023 $2,610 $199 $58–$717 $160
2024 $2,117 $206 $62–$740 $164
2025 $2,410 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $1,466 138 payments
  2. Mayne Pharma Inc. $1,354 155 payments
  3. AbbVie, Inc. $1,142 90 payments
  4. Sun Pharmaceutical Industries Inc. $1,049 67 payments
  5. Genzyme Corporation $833 25 payments
  6. Lilly USA, LLC $810 50 payments
  7. Incyte Corporation $801 58 payments
  8. Pfizer Inc. $786 51 payments
  9. Janssen Biotech, Inc. $785 52 payments
  10. Almirall LLC $708 36 payments
  11. Other $3,124 218 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,260 935 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $410 2 payments
  3. Education $187 3 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $950 30 payments
  2. OPZELURA $801 58 payments
  3. TALTZ $791 48 payments
  4. TREMFYA $726 48 payments
  5. EUCRISA $668 44 payments
  6. Klisyri $638 31 payments
  7. SKYRIZI $621 48 payments
  8. CIBINQO $592 39 payments
  9. Winlevi $580 36 payments
  10. COSENTYX $544 48 payments
  11. Other $7,642 546 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

679

Median for Physician Assistant: 241

Drug cost

$137,636

Median for Physician Assistant: $4,110

Branded share of claims

4.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 29 $117,727
Clobetasol Propionate Generic 72 $4,349
Fluorouracil Generic 49 $3,524
Betamethasone Dipropionate Generic 61 $2,803
Metronidazole Generic 27 $1,798
Triamcinolone Acetonide Generic 119 $1,343
Clindamycin Phosphate Generic 44 $1,279
Ketoconazole Generic 108 $1,268
Fluocinonide Generic 23 $1,058
Minocycline Hcl Generic 27 $843

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$85,948

Of which drugs: $12

Medicare patients

673

Average age 74

Services billed

3,140

322 women, 351 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 45%
Ischemic heart disease 27%
Diabetes 22%
Chronic kidney disease 17%
Depression 17%
Atrial fibrillation 16%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 15 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $142
  • Regeneron Healthcare Solutions, Inc. $83
$225 29 —
SKYRIZI
  • AbbVie, Inc. $207
$207 — —
Klisyri
  • Almirall LLC $199
$199 — —
OPZELURA
  • Incyte Corporation $192
$192 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $167
$167 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

940 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record